Trial · NCT07911124
Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
NCT07911124, Phase 2, Recruiting, University of Arkansas
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease. Trials, record NCT07911124. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911124
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
- NCT number
- NCT07911124
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 230 participants, estimated
- Lead sponsor
- University of Arkansas
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist, Placebo
- First posted
- 2026-11-02
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Aim 1: post-treatment IL-1β value | from baseline (day 0) to post-treatment (day 42) | Blood (Serum IL-1β) will be drawn at baseline (Day 0) and post-treatment (Day 42) and analyzed to determine if mean reduction in IL-1β is significantly higher in the ticagrelor arm than the placebo arm. To determine the clinical relevance of this cytokine reduction on surrogate markers of cardiovascular risk. |
| Secondary | Aim 1: effect of ticagrelor on additional markers | from baseline (day 0) to post-treatment (day 42) for additional markers, and to day 72 for washout analysis | Will evaluate the effect of ticagrelor monotherapy on additional inflammatory markers, surrogate cardiovascular markers, and safety outcomes in CKD patients after 42 days of treatment. Will determine whether the anti-inflammatory effects of ticagrelor persist after a 30-day drug washout period (Day 72) by comparing serum cytokine levels and UACR at Day 72 to Day 0 in the ticagrelor arm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HL187306 | Effect of Platelet Inhibition with Ticagrelor to Reduce Inflammation and Surrogate Cardiovascular Markers in Patients with Chronic Kidney Disease | Jain, Nishank | UNIV OF ARKANSAS FOR MED SCIS | NATIONAL HEART LUNG AND BLOOD INSTITUTE | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911124
GET https://conductscience.org/api/trials/v1/NCT07911124/registered